NasdaqCM:BLTEPharmaceuticals
Is Tinlarebant’s Rolling NDA for Stargardt Disease Altering The Investment Case For Belite Bio (BLTE)?
Belite Bio recently initiated a rolling New Drug Application submission to the U.S. FDA for tinlarebant, an investigational oral therapy for Stargardt disease type 1, following completion of a Phase 3 trial and multiple regulatory designations including Breakthrough Therapy and Orphan Drug status.
This step positions tinlarebant as a potential first approved treatment for Stargardt disease and highlights Belite Bio’s advancing regulatory and commercialization plans in rare retinal...